Esophageal carcinoma with SMARCA4 mutation: Unique diagnostic challenges
Pathology - Research and Practice · 2023
DOI: 10.1016/j.prp.2023.154692 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology - Research and Practice, 2023. Verfasst von Min Cui und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA. Electronic address: mcui24@wisc.edu. Hauptthemen laut MEDLINE: Carcinoma, Esophageal Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
Esophageal carcinoma with SMARCA4 deficiency or dysfunction is a recently recognized entity. This study describes the clinicopathologic features of four cases of esophageal carcinoma with SMARCA4 mutation, three with deep deletion and one with missense mutation. Patients include 3 males and 1 female, with an age range of 45-68 years old. Histologically, the neoplasms showed frequent mitotic activity, large nucleus and prominent nucleoli. Glandular differentiation was variable from not identifiable to approximately 20% in the biopsy material. Percentage of rhabdoid morphology was also variable from not identifiable to 20% of the biopsy material. For these cases, one case was diagnosed SMARCA4 deficient esophageal carcinoma based on the biopsy of a retroperitoneal lymph node showing loss of BRG1 by immunostain, and next generation sequencing confirmed deep deletion of SMARCA4. The other three cases had diagnosis of undifferentiated carcinoma or poorly differentiated carcinoma, and the SMARCA4 deep deletion or mutation was discovered by next generation sequencing. Molecular analysis showed TP53 mutation in all the three cases with SMARCA4 deep deletion. Two of the patients deceased 72 and 78 days after diagnosis, and the other two patients showed limited or no treatment response to chemotherapy. In conclusion, esophageal carcinoma with SMARCA4 mutation may pose significant diagnostic challenge for surgical pathologists due to its variable morphology and immunoprofile, and accurate classification of this entity requires recognition of the spectrum of morphology and utilization of BRG1 immunostain and next generating sequencing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA. Electronic address: mcui24@wisc.edu.
- Division of Hematology and Oncology, Department of Medicine, University of Wisconsin, Madison, WI, USA.
- Department of Pathology, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA.
Zitieren
APA
Cui, M., Lemmon, K., Jin, Z., & Uboha, N. V. (2023). Esophageal carcinoma with SMARCA4 mutation: Unique diagnostic challenges. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2023.154692
Vancouver
Cui M, Lemmon K, Jin Z, Uboha NV. Esophageal carcinoma with SMARCA4 mutation: Unique diagnostic challenges. Pathology - Research and Practice. 2023. doi:10.1016/j.prp.2023.154692
BibTeX
@article{Cui2023,
author = {Cui, Min and Lemmon, Kayla and Jin, Zhicheng and Uboha, Nataliya V},
title = {Esophageal carcinoma with SMARCA4 mutation: Unique diagnostic challenges},
journal = {Pathology - Research and Practice},
year = {2023},
doi = {10.1016/j.prp.2023.154692}
}
EUVIMED